A 32-year-old woman with moderate persistent asthma has been prescribed inhaled fluticasone propionate 250 μg twice daily for 6 months. She reports good symptom control with reduced exacerbations. On routine follow-up, you note she has developed oral candidiasis and mild hoarseness. Her serum cortisol at 8 AM is 18 μg/dL (normal: 10–20 μg/dL). Which of the following is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has developed **local adverse effects** of inhaled corticosteroids (oral candidiasis and dysphonia) despite adequate disease control and normal systemic cortisol levels. The goal is to preserve therapeutic benefit while mitigating these preventable local complications. ## Local vs. Systemic Toxicity **Key Point:** Oral candidiasis and hoarseness are **local oropharyngeal effects** caused by direct deposition of inhaled corticosteroid particles on the mucosa — not systemic absorption. Normal serum cortisol rules out clinically significant HPA axis suppression. **High-Yield:** The two most effective strategies to prevent local ICS toxicity are: 1. **Mouth rinsing** with water immediately after inhalation (removes residual drug from oropharynx) 2. **Spacer device** (reduces oropharyngeal deposition, increases lung delivery, improves efficacy) ## Why This Approach Works | Intervention | Mechanism | Evidence | |---|---|---| | Mouth rinsing | Physically removes deposited particles from oropharynx | Reduces candidiasis incidence by ~50% | | Spacer device | Reduces particle size, improves lung deposition, decreases oropharyngeal impact | Increases FEV₁ response; reduces local side effects | | Technique education | Ensures proper inhalation technique | Critical for reducing oropharyngeal deposition | **Clinical Pearl:** A spacer not only reduces local toxicity but *improves* drug delivery to the lungs, often allowing dose reduction without loss of control. ## Why Dose Reduction Is Not First-Line Here The patient has **good asthma control** on the current dose. Reducing the dose risks loss of control and rebound exacerbations. Local side effects are reversible with technique modification; loss of asthma control is not. [cite:KD Tripathi 8e Ch 28] [cite:Harrison 21e Ch 297]